Reckitt Benckiser Group plc (RKT.L)
Slough, ENG, GB
Reckitt Benckiser Group Plc engages in the manufacture and trade of consumer brand products including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, and Woolite. It operates through the following segments: Hygiene, Health, and Nutrition. The company was founded by Isaac Reckitt in 1840 and is headquartered in Slough, the United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.96% | -2.17% | -1.86% | -29.50% | -24.69% | -26.57% | -11.53% | -29.44% | -31.20% | -35.89% | +1,044.92% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 9 | 0 |
| Hold | 6 | -2 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Household & Personal Products: +3.3%+0.3% Q4'25: +0.9% (vs Q4'23)
-
EPS growth Household & Personal Products: +8.8%+139.9% ★ Q4'25: +508.9% (vs Q4'23)
-
FCF margin FCF growth · Household & Personal Products: +44.8%+20.1% ★ Q4'25: +15.3% (vs Q4'23)
-
EBIT margin Household & Personal Products: +9.9%+29.7% ★ Q4'25: +37.6% (vs Q4'23)
-
ROIC Household & Personal Products: +8.2%+24.7% ★ Q4'25: +67.6% (vs Q4'23)
-
Share dilution Household & Personal Products: +0.2%-6.8% ★ Q4'25: -9.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Household & Personal Products: -0.51×2.00× Q4'25: 0.78× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 17 Rev. Ana. 13 EPS Ana. |
Dec 2027 15 Rev. Ana. 12 EPS Ana. |
Dec 2028 6 Rev. Ana. 7 EPS Ana. |
Dec 2029 11 Rev. Ana. 10 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.87B
est: 8.83B (+0.5%)
|
9.48B
est: 9.87B (-3.9%)
|
11.45B
est: 11.58B (-1.1%)
|
12.60B
est: 12.56B (+0.3%)
|
12.85B
est: 12.83B (+0.1%)
|
13.99B
est: 13.99B (0.0%)
|
13.23B
est: 13.12B (+0.8%)
|
14.45B
est: 14.40B (+0.4%)
|
14.61B
est: 14.33B (+1.9%)
|
14.17B
est: 14.20B (-0.2%)
|
14.21B
est: 14.23B (-0.2%)
|
12.75B
12.29B – 13.06B
-10.4% YoY
|
13.23B
13.02B – 13.48B
+3.8% YoY
|
13.76B
13.41B – 14.05B
+4.0% YoY
|
14.17B
13.81B – 14.48B
+3.0% YoY
|
15.37B
14.98B – 15.70B
+8.5% YoY
|
| EBITDA |
2.42B
est: 1.73B (+39.9%)
|
2.48B
est: 1.94B (+28.3%)
|
2.98B
est: 2.27B (+31.2%)
|
3.50B
est: 2.46B (+42.1%)
|
-1.32B
est: 2.52B (-152.5%)
|
3.49B
est: 2.75B (+27.0%)
|
465.00M
est: 2.57B (-81.9%)
|
3.90B
est: 2.83B (+38.2%)
|
3.19B
est: 6.68B (-52.3%)
|
2.95B
est: 6.62B (-55.5%)
|
4.22B
est: 6.64B (-36.4%)
|
5.94B
5.73B – 6.09B
-10.4% YoY
|
6.17B
6.07B – 6.28B
+3.8% YoY
|
6.41B
6.25B – 6.55B
+4.0% YoY
|
6.61B
6.44B – 6.75B
+3.0% YoY
|
7.17B
6.99B – 7.32B
+8.5% YoY
|
| EBIT |
2.25B
est: 1.43B (+57.9%)
|
2.31B
est: 1.60B (+45.1%)
|
2.75B
est: 1.87B (+47.1%)
|
3.10B
est: 2.03B (+52.6%)
|
-1.76B
est: 2.07B (-184.8%)
|
3.15B
est: 2.26B (+39.2%)
|
7.00M
est: 2.12B (-99.7%)
|
3.30B
est: 2.33B (+41.7%)
|
2.71B
est: 6.99B (-61.2%)
|
2.50B
est: 6.93B (-63.9%)
|
4.22B
est: 6.94B (-39.2%)
|
6.21B
5.99B – 6.37B
-10.4% YoY
|
6.45B
6.35B – 6.57B
+3.8% YoY
|
6.71B
6.54B – 6.85B
+4.0% YoY
|
6.91B
6.74B – 7.06B
+3.0% YoY
|
7.50B
7.30B – 7.66B
+8.5% YoY
|
| Net Income |
1.74B
est: 1.69B (+2.9%)
|
1.83B
est: 2.07B (-11.5%)
|
3.38B
est: 2.28B (+48.1%)
|
2.16B
est: 2.29B (-5.5%)
|
-2.77B
est: 2.32B (-219.3%)
|
1.19B
est: 2.28B (-48.0%)
|
-32.00M
est: 2.04B (-101.6%)
|
2.33B
est: 2.35B (-1.0%)
|
1.64B
est: 1.41B (+16.2%)
|
1.43B
est: 2.15B (-33.7%)
|
3.18B
est: 2.36B (+34.8%)
|
2.17B
2.07B – 2.26B
-8.0% YoY
|
2.49B
2.30B – 2.51B
+14.5% YoY
|
2.51B
2.43B – 2.58B
+1.0% YoY
|
2.66B
2.57B – 2.73B
+5.7% YoY
|
2.99B
2.89B – 3.07B
+12.4% YoY
|
| SGA |
2.75B
est: 3.04B (-9.5%)
|
3.03B
est: 3.39B (-10.8%)
|
3.52B
est: 3.98B (-11.7%)
|
4.06B
est: 4.32B (-6.0%)
|
4.36B
est: 4.41B (-1.1%)
|
5.00B
est: 4.81B (+4.0%)
|
4.65B
est: 4.51B (+3.0%)
|
4.64B
est: 4.95B (-6.2%)
|
5.09B
est: 4.79B (+6.1%)
|
4.83B
est: 4.75B (+1.7%)
|
4.42B
est: 4.76B (-7.2%)
|
4.26B
4.11B – 4.37B
-10.4% YoY
|
4.43B
4.36B – 4.51B
+3.8% YoY
|
4.60B
4.48B – 4.70B
+4.0% YoY
|
4.74B
4.62B – 4.84B
+3.0% YoY
|
5.14B
5.01B – 5.25B
+8.5% YoY
|
| EPS |
2.44
est: 2.41 (+1.0%)
|
2.60
est: 2.95 (-11.8%)
|
4.81
est: 3.25 (+48.1%)
|
3.06
est: 3.26 (-6.1%)
|
-3.91
est: 3.31 (-218.1%)
|
1.67
est: 3.25 (-48.7%)
|
-0.05
est: 2.91 (-101.5%)
|
3.27
est: 3.45 (-5.3%)
|
2.29
est: 2.17 (+5.7%)
|
2.04
est: 3.30 (-38.1%)
|
4.88
est: 3.62 (+34.8%)
|
3.34
3.16 – 3.45
-7.8% YoY
|
3.60
3.51 – 3.84
+8.0% YoY
|
3.84
3.72 – 3.95
+6.7% YoY
|
4.06
3.93 – 4.18
+5.7% YoY
|
4.57
4.41 – 4.69
+12.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kristoffer Loe Licht | Chief Executive Officer & Executive Director | 4M | male |
| Shannon Sue Eisenhardt | Chief Financial Officer & Executive Director | 3M | female |
| Catheryn O'Rourke | Senior Vice President, General Counsel & Company Secretary | — | female |
| Jerome Lemaire | President North America | — | male |
| Nicholas James Ashworth | Senior Vice President of Investor Relations | — | male |
| Ranjay Radhakrishnan | Chief Human Resources Officer | — | male |
| Sheila Redzepi | Chief Communications & Corporate Affairs Officer | — | female |
| Alessio Fasano | Chief Science & Medical Officer of Mead Johnson Nutrition (MJN) Business | — | — |
| Susan Sholtis | President of Nutrition | — | female |
| Angela Naef | Chief Research & Development Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RKT.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
